Functional polymorphisms in genes of the Angiotensin and Serotonin systems and risk of hypertrophic cardiomyopathy: AT1R as a potential modifier

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Coto, Eliecer ^a,c   Palacín, María ^a   Martín, María ^a   Castro, Mónica G ^a   Reguero, Julián R ^a   García, Cristina ^a   Berrazueta, José R ^b   Morís, César ^a   Morales, Blanca ^a   Ortega, Francisco ^a   Corao, Ana I ^a   Díaz, Marta ^a   Tavira, Beatriz ^a   Alvarez, Victoria ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c UNIVERSITY OF OVIEDO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; ANGIOTENSIN DERIVATIVE;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CHILD; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONSET AGE; SCHOOL CHILD; SEROTONINERGIC SYSTEM; CASE CONTROL STUDY; GENETICS; MIDDLE AGED; MUTATION;

ADOLESCENT; ADULT; AGED; ANGIOTENSINS; CARDIOMYOPATHY, HYPERTROPHIC; CASE-CONTROL STUDIES; CHILD; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; RECEPTOR, ANGIOTENSIN, TYPE 1; SEROTONIN; YOUNG ADULT;

EID: 77954070790     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-64     Document Type: Article

References (40)

1. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997, 59:551-571. 10.1146/annurev.physiol.59.1.551, 9074777.
2. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000, 102:470-479.
3. Bos JM, Towbin JA, Ackerman MJ. Diagnostic prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009, 54:201-211. 10.1016/j.jacc.2009.02.075, 19589432.
4. Bleumink GS, Schut AF, Sturkenboom MC, Deckers JW, van Duijn CM, Stricker BH. Genetic polymorphisms and heart failure. Genet Med 2004, 6:465-474. 10.1097/01.GIM.0000144061.70494.95, 15545741.
5. Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med 2008, 5:158-168. 10.1038/ncpcardio1110, 18227814.
6. Perkins MJ, Van Driest SL, Ellsworth EG, Will ML, Gersh BJ, Ommen SR, Ackerman MJ. Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. Eur Heart J 2005, 26:2457-2462. 10.1093/eurheartj/ehi438, 16087648.
7. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006, 7:589-600. 10.1038/nrm1983, 16936699.
8. Jaffré F, Bonnin P, Callebert J, Debbabi H, Setola V, Doly S, Monassier L, Mettauer B, Blaxall BC, Launay JM, Maroteaux L. Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res 2009, 104:113-123. 10.1161/CIRCRESAHA.108.180976, 19023134.
9. Jaffré F, Callebert J, Sarre A, Etienne N, Nebigil CG, Launay JM, Maroteaux L, Monassier L. Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1 beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts. Circulation 2004, 110:969-974. 10.1161/01.CIR.0000139856.20505.57, 15302781.
10. Sano M, Fukuda K, Kodama H, Pan J, Saito M, Matsuzaki J, Takahashi T, Makino S, Kato T, Ogawa S. Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem 2000, 275:29717-29723. 10.1074/jbc.M003128200, 10843995.
11. Cerrito F, Lazzaro MP, Gaudio E, Arminio P, Aloisi G. 5HT2-receptors and serotonin release their role in human platelet aggregation. Life Sci 1993, 53:209-215. 10.1016/0024-3205(93)90671-O, 8321084.
12. Eddahibi S, Fabre V, Boni C, Martres MP, Raffestin B, Hamon M, Adnot S. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin. Circ Res 1999, 84:329-336.
13. Dorn GW, Tepe NM, Lorenz JN, Koch WJ, Liggett SB. Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice. Proc Natl Acad Sci USA 1999, 96:6400-6405. 10.1073/pnas.96.11.6400, 26893, 10339599.
14. Nebigil CG, Maroteaux L. Functional consequence of serotonin/5-HT2B receptor signaling in heart: role of mitochondria in transition between hypertrophy and heart failure?. Circulation 2003, 108:902-908. 10.1161/01.CIR.0000081520.25714.D9, 12925446.
15. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, Sham P, Kerwin R. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995, 346:281-282. 10.1016/S0140-6736(95)92168-0, 7630250.
16. Greenberg BD, Tolliver TJ, Huang S-H, Li Q, Bengel D, Murphy DL. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J MedGenet 1999, 88:83-87.
17. D'Souza UM, Craig IW. Functional genetic polymorphisms in serotonin and dopamine gene systems and their significance in behavioural disorders. Prog Brain Res 2008, 172:73-98. full_text, 18772028.
18. Harrap SB, Dominiczak AF, Fraser R, Lever AF, Morton JJ, Foy CJ, Watt GCM. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996, 93:1148-1154.
19. Johnson DB, Foster RE, Barilla F, Blackwell GG, Roney M, Stanley AWH, Kirk K, Orr RA, van der Geest RJ, Reiber JHC. Dell'Italia LJ. Angiotensin-converting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction < 40% after acute myocardial infarction. J Am Coll Cardiol 1997, 29:49-54. 10.1016/S0735-1097(96)00451-2, 8996294.
20. Wang JG, Staessen JA. Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease. Eur J Pharmacol 2000, 410:289-302. 10.1016/S0014-2999(00)00822-0, 11134677.
21. Hebert PR, Foody JM, Hennekens CH. The renin-angiotensin system: the role of inhibitors, blockers, and genetic polymorphisms in the treatment and prevention of heart failure. Curr Vasc Pharmacol 2003, 1:33-39. 10.2174/1570161033386655, 15320851.
22. Lechin M, Quinones MA, Omran A, Hill R, Yu QT, Rakowski H, Wigle D, Liew CC, Sole M, Roberts R, Marian AJ. Angiotensin I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation 1995, 92:1808-1812.
23. Tesson F, Dufour C, Moolman JC, Carrier L, Al-Mahdawi S, Chojnowska L, Dubourg O, Soubrier F, Brink P, Komajda M, Guicheney P, Schwartz K, Feingold J. The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. J Mol Cell Cardiol 1997, 29:831-838. 10.1006/jmcc.1996.0332, 9140839.
24. Benetos A, Gautier S, Ricard S, Topouchian J, Asmar R, Poirier O, Larosa E, Guize L, Safar M, Soubrier F, Cambien F. Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation 1996, 94:698-703.
25. Nakauchi Y, Suehiro T, Yamamoto M, Yasuoka N, Arii K, Kumon Y, Hamashige N, Hashimoto K. Significance of angiotensin I-converting enzyme and angiotensin II type 1 receptor gene polymorphisms as risk factors for coronary heart disease. Atherosclerosis 1996, 125:161-169. 10.1016/0021-9150(96)05866-2, 8842348.
26. Amant C, Hamon M, Bauters C, Richard F, Helbecque N, McFadden EP, Escudero X, Lablanche JM, Amouyel P, Bertrand ME. The angiotensin II type 1 receptor gene polymorphism is associated with coronary artery vasoconstriction. J Am Coll Cardiol 1997, 29:486-490. 10.1016/S0735-1097(96)00535-9, 9060882.
27. Osterop AP, Kofflard MJ, Sandkuijl LA, ten Cate FJ, Krams R, Schalekamp MA, Danser AH. T1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Hypertension 1998, 32:825-830.
28. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463. 10.1016/j.echo.2005.10.005, 16376782.
29. García-Castro M, Reguero JR, Batalla A, Díaz-Molina B, González P, Alvarez V, Cortina A, Cubero GI, Coto E. Hypertrophic cardiomyopathy: low frequency of mutations in the beta-myosin heavy chain (MYH7) and cardiac troponin T (TNNT2) genes among Spanish patients. Clin Chem 2003, 49:1279-1285. 10.1373/49.8.1279, 12881443.
30. García-Castro M, Coto E, Reguero JR, Berrazueta JR, Alvarez V, Alonso B, Sainz R, Martín M, Morís C. Mutations in sarcomeric genes MYH7, MYBPC3, TNNT2, TNNI3, and TPM1 in patients with hypertrophic cardiomyopathy. Rev Esp Cardiol 2009, 62:48-56. 10.1016/S1885-5857(09)71513-0, 19150014.
31. Alvarez R, Reguero JR, Batalla A, Iglesias-Cubero G, Cortina A, Alvarez V, Coto E. Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease. Cardiovasc Res 1998, 40:375-379. 10.1016/S0008-6363(98)00179-5, 9893731.
32. Coto E, Reguero JR, Alvarez V, Morales B, Batalla A, González P, Martín M, García-Castro M, Iglesias-Cubero G, Cortina A. 5-Hydroxytryptamine 5-HT2A receptor and 5-hydroxytryptamine transporter polymorphisms in acute myocardial infarction. Clin Sci (Lond) 2003, 104:241-245. 10.1042/CS20020246, 12605580.
33. Coto E, Rodrigo L, Alvarez R, Fuentes D, Rodríguez M, Menéndez LG, Ciriza C, González P, Alvarez V. Variation at the Angiotensin-converting enzyme and endothelial nitric oxide synthase genes is associated with the risk of esophageal varices among patients with alcoholic cirrhosis. J Cardiovasc Pharmacol 2001, 38:833-839. 10.1097/00005344-200112000-00004, 11707686.
34. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000, 15:7-12. 10.1002/(SICI)1098-1004(200001)15:1<7::AID-HUMU4>3.0.CO;2-N, 10612815.
35. Brugada R, Kelsey W, Lechin M, Zhao G, Yu QT, Zoghbi W, Quinones M, Elstein E, Omran A, Rakowski H, Wigle D, Liew CC, Sole M, Roberts R, Marian AJ. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. J Invest Med 1997, 45:542-551.
36. Martin MM, Buckenberger JA, Jiang J, Malana GE, Nuovo GJ, Chotani M, Feldman DS, Schmittgen TD, Elton TS. The human angiotensin II type 1 receptor + 1166 A/C polymorphism attenuates microrna-155 binding. J Biol Chem 2007, 282:24262-24269. 10.1074/jbc.M701050200, 2413065, 17588946.
37. Su X, Lee L, Li X, Lv J, Hu Y, Zhan S, Cao W, Mei L, Tang YM, Wang D, Krauss RM, Taylor KD, Rotter JI, Yang H. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation 2007, 115:725-732. 10.1161/CIRCULATIONAHA.106.642058, 17261659.
38. Abdollahi MR, Lewis RM, Gaunt TR, Cumming DV, Rodriguez S, Rose-Zerilli M, Collins AR, Syddall HE, Howell WM, Cooper C, Godfrey KM, Cameron IT, Day IN. Quantitated transcript haplotypes (QTH) of AGTR1, reduced abundance of mRNA haplotypes containing 1166C (rs5186:A > C), and relevance to metabolic syndrome traits. Hum Mutat 2007, 28:365-373. 10.1002/humu.20454, 17211857.
39. Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S. ONTARGET/TRANSCEND Investigators. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation 2009, 120:1380-1389. 10.1161/CIRCULATIONAHA.109.865774, 19770395.
40. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nyström F, Hägg A, Lind L. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 2002, 20:657-663. 10.1097/00004872-200204000-00023, 11910301.